Basic Information

Common Name
B-hVEGFA MC38(service only)
Catalog Number
322309
Alias
L-VEGF, MVCD1, VEGF, VPF
Disease
Colon carcinoma
Organism
Mouse
Strain
C57BL/6
Tissue
Colon
Tissue types
Colon
Application
B-hVEGFA MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.
NCBI Gene ID

Description

This cell line is for service only.

The mouse Vegfa gene was replaced by human VEGFA coding sequence in B-hVEGFA MC38 cells.

Protein expression analysis

B-hVEGFA MC38

VEGFA expression analysis in B-hVEGFA MC38 cells by ELISA. Cell culture supernatant collected from wild-type MC38 and B-hVEGFA MC38, and analyzed by ELISA with species-specific VEGFA kit. Mouse VEGFA was detectable in the culture supernatant of wild-type MC38 cells. Human VEGFA was detectable in the culture supernatant of B-hVEGFA MC38 cells but not in that of wild-type MC38 cells. The 2-C05 clone of B-hVEGFA MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

B-hVEGFA MC38

Subcutaneous homograft tumor growth of B-hVEGFA MC38 cells. Wild-type MC38 cells (5×105) and B-hVEGFA MC38 cells (5×105) were subcutaneously implanted into C57BL/6 and B-hVEGFA mice (female, 8-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hVEGFA MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-hVEGFA MC38
Wild-type MC38 cells and B-hVEGFA MC38 cells were subcutaneously transplanted into C57BL/6 mice and B-hVEGFA mice (n=5). At the end of the experiment, Tumor tissue homogenate were assessed for mouse and human VEGFA expression by ELISA. As shown, mouse VEGFA was expressed in the group (G1, G2, G3), human VEGFA was expressed in the group (G2, G3, G4). Therefore, B-hVEGFA MC38 cells can be used for in vivo efficacy studies of novel VEGFA therapeutics.

Back to top